The P-III study (LIBRETTO-431) evaluating Retevmo vs Pt-based CT + pemetrexed with/out pembrolizumab in a ratio (2:1) in 261 patients with RET fusion+ advanced or metastatic NSCLC, based on a pre-specified interim efficacy analysis conducted by IDMC
The study met its 1EPs & showed a significant and clinical improvement in PFS, AEs were generally consistent with those identified across the previously reported Retevmo development program. The results will submit to a peer-reviewed journal and discussed with health authorities
Retevmo, a highly selective and potent RET kinase inhibitor with CNS activity that may affect both tumor cells and healthy cells resulted in side effects
Ref: Eli Lilly | Image: Eli Lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
